Research Article: Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study
Abstract:
A significant breakthrough has been made in treating severe asthma, with the recognition of various asthma phenotypes and an updated management guideline. Type 2 targeted therapies, such as benralizumab and omalizumab; have been identified as an effective treatment for severe asthma, improving patient response, lung function tests and asthma symptom control. This study aimed to evaluate factors contributing to poor response to therapy.
Introduction:
Asthma is a commonrespiratory disease that affects a large number ofpeople and can significantly impact their quality of life. It ranks 16th and 28th globally among the top cause of morbidity and mortality. Approximately 300 million people worldwide have asthma, which is expected to affect an additional 100 million by 2025 [1]. The prevalence, severity, and mortality rates of asthma vary across different regions, with higher rates in high-income countries but more deaths in low- and middle-income countries [2].
Read more